As the most common ligands of Notch during angiogenesis that are also found to be upregulated in cancer, Dll4 and Jag1 have both been targeted for treatment of breast cancer tumors, with Dll4 being a more established focus point (111, 112). Here, DLL4 is linked to breast cancer.